Drug Trial Radar · NCT07677215
ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Sep 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Poznan University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective randomized controlled trial aims to compare the analgesic efficacy and safety of three adjuvant strategies for ultrasound-guided Adductor Canal Block (ACB) and iPACK block in patients undergoing elective total knee arthroplasty under spinal anesthesia. All participants will receive standardized spinal anesthesia with 0.5% ropivacaine combined with ACB and iPACK blocks using 0.2% ropivacaine. Patients will be randomized into one of three groups: standard ACB + iPACK without adjuvants, ACB + iPACK with intravenous dexamethasone 8 mg, or ACB + iPACK with intravenous dexamethasone 8 mg combined with perineural dexmedetomidine added to both regional blocks. The primary outcome will be total postoperative opioid consumption during the first 48 hours after surgery expressed as intravenous morphine equivalents. Secondary outcomes will include pain intensity at rest and during movement, duration of analgesia, time to first rescue analgesia, quadriceps muscle strength, early mobilization, adverse events, inflammatory markers, and length of hospital stay.
Conditions
- Knee Osteoarthritis
Interventions
Ropivacaine 0.2% Injectable SolutionDrug
Ropivacaine 0.2% used for ultrasound-guided ACB and iPACK blocks (20 mL per block).
DexamethasoneDrug
Intravenous dexamethasone 8 mg administered perioperatively.
DexmedetomidineDrug
Perineural dexmedetomidine 12.5 μg added to each regional block (ACB and iPACK).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total postoperative opioid consumption during the first 48 hours after surgeryTime frame: 48 hours after surgery
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The John Paul II Catholic University of Lublin
Lublin, Poland · Recruiting
Poznan University of Medical Sciences
Poznan, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.